Evidence map›Paper›PMID 39171592›Full record

ArticleCurrent protein & peptide science2025

Utilizing AfDesign for Developing a Small Molecule Inhibitor of PICK- 1-PDZ.

Emily Hendrix, Xinyu Xia, Amy O Stevens, Yi He

Abstract read
PubMed Publisher
In one paragraph

Article in Current protein & peptide science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily HendrixDepartment of Chemistry and Chemical Biology, The University of New Mexico, Albuquerque, New Mexico 87131, USA.
Xinyu XiaDepartment of Chemistry and Chemical Biology, The University of New Mexico, Albuquerque, New Mexico 87131, USA.
Amy O StevensDepartment of Chemistry and Chemical Biology, The University of New Mexico, Albuquerque, New Mexico 87131, USA.
Yi HeDepartment of Chemistry and Chemical Biology, The University of New Mexico, Albuquerque, New Mexico 87131, USA.ORCID 0000-0002-6884-5312

Funding

National Science Foundation 2237369
6 · The paper itself

Abstract

introductionThe PICK1 PDZ domain has been identified as a potential drug target for neurological disorders. After many years of effort, a few inhibitors, such as TAT-C5 and mPD5, have been discovered experimentally to bind to the PDZ domain with a relatively high binding affinity. With the rapid growth of computational research, there is an urgent need for more efficient computational methods to design viable ligands that target proteins.

methodsRecently, a newly developed program called AfDesign (part of ColabDesign) at https:// github.com/sokrypton/ColabDesign), an open-source software built on AlphaFold, has been suggested to be capable of generating ligands that bind to targeted proteins, thus potentially facilitating the ligand development process. To evaluate the performance of this program, we explored its ability to target the PICK1 PDZ domain, given our current understanding of it. We found that the designated length of the ligand and the number of recycles play vital roles in generating ligands with optimal properties.

resultsUtilizing AfDesign with a sequence length of 5 for the ligand produced the highest comparable ligands to that of prior identified ligands. Moreover, these designed ligands displayed significantly lower binding energy compared to manually created sequences.

conclusionThis work demonstrated that AfDesign can potentially be a powerful tool to facilitate the exploration of the ligand space for the purpose of targeting PDZ domains.

Indexed as

Carrier ProteinsNuclear ProteinsPDZ DomainsSmall Molecule LibrariesSoftwareBinding SitesDrug DesignHumansLigandsProtein BindingCarrier ProteinsLigandsNuclear ProteinsPICk1 protein, humanSmall Molecule LibrariesAfDesignAlphaFold.ColabFoldinhibitorPDZPICK1

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.